fms-Like Tyrosine Kinase 3
"fms-Like Tyrosine Kinase 3" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A receptor tyrosine kinase that is involved in HEMATOPOIESIS. It is closely related to FMS PROTO-ONCOGENE PROTEIN and is commonly mutated in acute MYELOID LEUKEMIA.
Descriptor ID |
D051941
|
MeSH Number(s) |
D08.811.913.696.620.682.725.400.020 D12.776.543.750.060.020 D12.776.624.664.700.114 D23.050.301.264.035.284 D23.101.100.110.284
|
Concept/Terms |
fms-Like Tyrosine Kinase 3- fms-Like Tyrosine Kinase 3
- fms Like Tyrosine Kinase 3
- Fetal Liver Kinase-2
- Fetal Liver Kinase 2
- Fetal Liver Kinase-3
- Fetal Liver Kinase 3
- CD135 Antigen
- Antigen, CD135
- Antigens, CD135
- CD135 Antigens
- Stem Cell Tyrosine Kinase 1
|
Below are MeSH descriptors whose meaning is more general than "fms-Like Tyrosine Kinase 3".
Below are MeSH descriptors whose meaning is more specific than "fms-Like Tyrosine Kinase 3".
This graph shows the total number of publications written about "fms-Like Tyrosine Kinase 3" by people in this website by year, and whether "fms-Like Tyrosine Kinase 3" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
2001 | 0 | 1 | 1 | 2002 | 0 | 1 | 1 | 2004 | 0 | 1 | 1 | 2005 | 0 | 1 | 1 | 2006 | 0 | 1 | 1 | 2007 | 2 | 0 | 2 | 2008 | 0 | 4 | 4 | 2009 | 0 | 3 | 3 | 2010 | 2 | 2 | 4 | 2011 | 2 | 2 | 4 | 2012 | 4 | 3 | 7 | 2013 | 2 | 3 | 5 | 2014 | 3 | 1 | 4 | 2015 | 1 | 0 | 1 | 2016 | 1 | 3 | 4 | 2017 | 3 | 0 | 3 | 2018 | 0 | 3 | 3 | 2019 | 1 | 2 | 3 | 2020 | 4 | 1 | 5 | 2021 | 6 | 1 | 7 |
To return to the timeline, click here.
Below are the most recent publications written about "fms-Like Tyrosine Kinase 3" by people in Profiles.
-
Rücker FG, Du L, Luck TJ, Benner A, Krzykalla J, Gathmann I, Voso MT, Amadori S, Prior TW, Brandwein JM, Appelbaum FR, Medeiros BC, Tallman MS, Savoie L, Sierra J, Pallaud C, Sanz MA, Jansen JH, Niederwieser D, Fischer T, Ehninger G, Heuser M, Ganser A, Bullinger L, Larson RA, Bloomfield CD, Stone RM, Döhner H, Thiede C, Döhner K. Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results. Leukemia. 2022 01; 36(1):90-99.
-
Richter WF, Shah RN, Ruthenburg AJ. Non-canonical H3K79me2-dependent pathways promote the survival of MLL-rearranged leukemia. Elife. 2021 07 15; 10.
-
Schmalbrock LK, Dolnik A, Cocciardi S, Sträng E, Theis F, Jahn N, Panina E, Blätte TJ, Herzig J, Skambraks S, Rücker FG, Gaidzik VI, Paschka P, Fiedler W, Salih HR, Wulf G, Schroeder T, Lübbert M, Schlenk RF, Thol F, Heuser M, Larson RA, Ganser A, Stunnenberg HG, Minucci S, Stone RM, Bloomfield CD, Döhner H, Döhner K, Bullinger L. Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin. Blood. 2021 06 03; 137(22):3093-3104.
-
Tang G, Tam W, Short NJ, Bose P, Wu D, Hurwitz SN, Bagg A, Rogers HJ, Hsi ED, Quesada AE, Wang W, Miranda RN, Bueso-Ramos CE, Medeiros LJ, Nardi V, Hasserjian RP, Arber DA, Orazi A, Foucar K, Wang SA. Myeloid/lymphoid neoplasms with FLT3 rearrangement. Mod Pathol. 2021 09; 34(9):1673-1685.
-
Takeda MR, Gurbuxani S. bcr3 PML-RARA: short fusion, small blasts! Blood. 2021 05 13; 137(19):2708.
-
Eisfelder BJ, Saygin C, Wynne J, Colton MW, Fischietti M, Beauchamp EM, Cheng JX, Odenike O, Roboz G, Alachkar H, Stock W. OTS167 blocks FLT3 translation and synergizes with FLT3 inhibitors in FLT3 mutant acute myeloid leukemia. Blood Cancer J. 2021 03 03; 11(3):48.
-
Larson RA, Mandrekar SJ, Huebner LJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, Thiede C, Prior TW, Döhner K, Marcucci G, Voso MT, Klisovic RB, Galinsky I, Wei AH, Sierra J, Sanz MA, Brandwein JM, de Witte T, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Krauter J, Schlenk RF, Ganser A, Serve H, Ehninger G, Amadori S, Gathmann I, Döhner H, Stone RM. Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial. Leukemia. 2021 09; 35(9):2539-2551.
-
Al Baghdadi T, Garrett-Mayer E, Halabi S, Mangat PK, Rich P, Ahn ER, Chai S, Rygiel AL, Osayameh O, Antonelli KR, Islam S, Bruinooge SS, Schilsky RL. Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Target Oncol. 2020 12; 15(6):743-750.
-
Bhardwaj N, Friedlander PA, Pavlick AC, Ernstoff MS, Gastman BR, Hanks BA, Curti BD, Albertini MR, Luke JJ, Blazquez AB, Balan S, Bedognetti D, Beechem JM, Crocker AS, D'Amico L, Danaher P, Davis TA, Hawthorne T, Hess BW, Keler T, Lundgren L, Morishima C, Ramchurren N, Rinchai D, Salazar AM, Salim BA, Sharon E, Vitale LA, Wang E, Warren S, Yellin MJ, Disis ML, Cheever MA, Fling SP. Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets. Nat Cancer. 2020 12; 1(12):1204-1217.
-
Voso MT, Larson RA, Jones D, Marcucci G, Prior T, Krauter J, Heuser M, Lavorgna S, Nomdedeu J, Geyer SM, Walker A, Wei AH, Sierra J, Sanz MA, Brandwein JM, de Witte TM, Jansen JH, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Schlenk RF, Ganser A, Amadori S, Cheng Y, Chen Y, Pallaud C, Du L, Piciocchi A, Ehninger G, Byrd J, Thiede C, Döhner K, Stone RM, Döhner H, Bloomfield CD, Lo-Coco F. Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial. Blood Adv. 2020 10 13; 4(19):4945-4954.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|